Program Target Potential Indication Discovery Preclinical IND-Enabling Phase 1 Ph 2/3 ADI-001 CD20 NHL ADI-001 CD20 Autoimmune ADI-270 CD70 (TGFβ-DNR) RCC & Other ST / Heme ADI-925* Tumor stress ligands Multiple Solid / Heme ADI-xxx PSMA (w/ Armor) mCRPC ADI-002+ GPC3 HCC Adicet Bio Pipeline *ADI-925 is an engineered Chimeric Adapter (CAd) γδ1 T cell product candidate targeting stress ligands, including MICA/MICB & ULBP1-6, expressed on malignant cells. The company has reprioritized its clinical pipeline to focus on ADI-270. Partnered programs Adicet wholly owned programs
Adicet Bio (ACET) 8-KAdicet Provides Corporate Update and Highlights Strategic Priorities for 2024
Filed: 4 Jan 24, 7:17am